Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access program of LOXO-292 for RET-activated advanced solid tumors
MOH_2019-06-25_007226Phase 2Not yet recruiting
- Sponsor
- Loxo Oncology
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selpercatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), thyroid cancer and 3 more, sponsored by Loxo Oncology. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
selpercatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)thyroid cancerMedullary Thyroid Cancer (MTC)pancreatic cancer (PC)
Beyond the preview
Go deeper on MOH_2019-06-25_007226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-25_007226.